Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidino
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Tokyo-based Atonarp Inc. announced today $8 million ... Walden Riverwood Ventures with participation from other co-investors.  ... Spectrometer technology platform, which will enable a broad ... oil & gas and healthcare industries for its ... partner with Atonarp in pursuing the commercialization of ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
(Date:8/19/2014)... , Aug. 19, 2014 According to ... component needed to make Big Data in healthcare a ... sales.  As part of the American Recovery and Reinvestment ... medical record (EMR) projects and penalties will start applying ... Kalorama Information, in its complete study of the EMR ...
Breaking Medicine Technology:Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey (Horizon ... teaming up during The Barclays at The Ridgewood County ... and Horizon BCBSNJ will be getting spectators into the walking ... own. , Horizon BCBSNJ, the official health care sponsor of ... to the New Jersey Golf Foundation, an organization that removes ...
(Date:8/19/2014)... News) -- Lupus and other rheumatic diseases can ... which can delay a correct diagnosis for months, ... diseases can also cause these types of symptoms, ... in Maywood, Ill. Rheumatic disorders include autoimmune ... tissues, such as lupus, systemic vasculitis and ankylosing ...
(Date:8/19/2014)... Grande Naturals, LLC is proud ... the 2014 Independent Cosmetics Manufacturers & Distributors Award ... position in “Product Innovation; Product Color Cosmetic” for ... includes a lash enhancement serum, GrandeLINER™. GrandeLINER™ ... , This all-new eyeliner is a ...
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Following the completion ... Grand Hyatt Tampa Bay is proud to debut the ... second project included a full revamp of all public spaces ... guest rooms and suites, an all-new dining experience at 1823 ... hotel lobby. , With the introduction of 1823 Kitchen and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2
... park is more than just a nice way to ... health, according to University of Illinois environment and behavior ... advocates, landscape architects, and popular writers have consistently claimed ... recently, their claims haven,t undergone rigorous scientific assessment." ...
... California, San Diego School of Medicine say antibodies to ... be useful as a future biomarker for predicting cancer ... concentration, used as a treatment for suppressing tumor growth. ... MD, assistant clinical professor of medicine, and Ajit Varki, ...
... News) -- Motorcycle deaths in the United States fell by about ... row fatalities have declined, according to a new report. The ... accidents in 2010 than in 2009, according to a report released ... estimated 4,465 were killed in 2009 compared to 4,376 in 2010. ...
... prohibition against testosterone therapy in men with untreated or ... study published in The Journal of Urology . ... a history of prostate cancer, even if treated and ... to the belief that testosterone activated prostate cancer growth, ...
... Translational Behavioral Medicine: Practice, Policy, Research (TBM), ... The journal will debut with a special section, ... Behavioral Medicine is an international, peer-reviewed journal ... is to engage, inform, and catalyze dialogue among ...
... study published in The American Journal on Addictions ... have high rates of substance use disorders. , Led by ... used national administrative data from the Department of Veterans Affairs ... served in Iraq and Afghanistan who were also diagnosed with ...
Cached Medicine News:Health News:Green environments essential for human health 2Health News:Green environments essential for human health 3Health News:Green environments essential for human health 4Health News:A cancer marker and treatment in 1? 2Health News:A cancer marker and treatment in 1? 3Health News:Motorcycle Deaths Drop for Second Straight Year: Report 2Health News:Study suggests another look at testosterone-prostate cancer link 2Health News:Study suggests another look at testosterone-prostate cancer link 3Health News:Springer launches new journal, Translational Behavioral Medicine: Practice, Policy, Research 2
... Radianse indoor positioning supports patient ... length-of-stay. Ensure the right patients are ... right procedures. Respond to the exact ... or a monitor alarms. Measure patient ...
MONOJECT MAGELLAN Safety Blood Collection Needle...
... Eclipse Blood Collection Needle consists of a ... a safety shield aligned to the bevel-up ... Vacutainer Eclipse Blood Collection Needle has its ... to attach a secondary safety accessory. Immediate, ...
... Shielding Blood Collection Needle is designed ... protection against needlesticks during a blood ... automatically upon insertion of the first ... the first tube is inserted through ...
Medicine Products: